David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 23.09% |
| 2 | Technology | 17.04% |
| 3 | Healthcare | 13.44% |
| 4 | Consumer Discretionary | 13.38% |
| 5 | Financials | 7.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2101
Vornado Realty Trust
VNO
$7.29B
| $2.06M | ﹤0.01% |
30,575
+15,426
| +102% | +$1.03M |
|
2102
Babcock & Wilcox
BW
$1.13B
| $2.06M | ﹤0.01% |
500,014
-162,508
| -25% | -$892K |
|
2103
Broadridge
BR
$21B
| $2.05M | ﹤0.01% |
+19,796
| New | +$1.99M |
|
|
LKSD
2104
DELISTED
LSC Communications, Inc.
LKSD
| $2.05M | ﹤0.01% |
314,465
+53,326
| +20% | +$417K |
|
2105
PUT
TSMC
TSM
$2.22T
| $2.05M | ﹤0.01% |
50,000
+30,000
| +150% | +$1.14M |
|
2106
CTS Corp
CTS
$1.64B
| $2.04M | ﹤0.01% |
69,427
+30,363
| +78% | +$891K |
|
|
PARA
2107
PUT
DELISTED
Paramount Global Class B
PARA
| $2.04M | ﹤0.01% |
42,900
-86,600
| -67% | -$4.22M |
|
2108
Ligand Pharmaceuticals
LGND
$5.64B
| $2.04M | ﹤0.01% |
25,977
-244,875
| -90% | -$18.6M |
|
2109
KB Home
KBH
$3.37B
| $2.03M | ﹤0.01% |
84,153
-59,212
| -41% | -$1.31M |
|
2110
Camping World
CWH
$412M
| $2.02M | ﹤0.01% |
+145,145
| New | +$2.03M |
|
2111
PUT
Allstate
ALL
$65.2B
| $2.02M | ﹤0.01% |
21,400
+8,700
| +69% | +$787K |
|
2112
Simpson Manufacturing
SSD
$7.48B
| $2.01M | ﹤0.01% |
33,937
+2,920
| +9% | +$173K |
|
|
BHVN
2113
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $2.01M | ﹤0.01% |
+39,037
| New | +$1.69M |
|
|
EPZM
2114
DELISTED
Epizyme, Inc
EPZM
| $2M | ﹤0.01% |
+161,611
| New | +$1.81M |
|
2115
PUT
Raymond James Financial
RJF
$33.7B
| $2M | ﹤0.01% |
37,350
| – | – |
|
|
CETV
2116
DELISTED
Central European Media Enterprises Ltd
CETV
| $2M | ﹤0.01% |
503,102
+151,125
| +43% | +$509K |
|
2117
ICF International
ICFI
$1.61B
| $2M | ﹤0.01% |
26,260
-26,122
| -50% | -$1.84M |
|
2118
BBVA Argentina
BBAR
$2.98B
| $2M | ﹤0.01% |
+210,073
| New | +$2.49M |
|
|
HTT
2119
High Templar Tech Ltd
HTT
$415M
| $1.99M | ﹤0.01% |
392,407
+366,617
| +1,422% | +$1.95M |
|
2120
Marvell Technology
MRVL
$220B
| $1.98M | ﹤0.01% |
99,709
+57,328
| +135% | +$1.07M |
|
|
ARRY
2121
DELISTED
Array Biopharma Inc
ARRY
| $1.98M | ﹤0.01% |
81,394
+64,794
| +390% | +$1.35M |
|
2122
OrthoPediatrics
KIDS
$607M
| $1.98M | ﹤0.01% |
44,833
+32,799
| +273% | +$1.25M |
|
2123
CALL
WD-40
WDFC
$2.95B
| $1.98M | ﹤0.01% |
11,700
-4,900
| -30% | -$863K |
|
|
RTL
2124
DELISTED
The Necessity Retail REIT, Inc. Class A Common Stock
RTL
| $1.98M | ﹤0.01% |
+183,225
| New | +$2.18M |
|
2125
Federal Realty Investment Trust
FRT
$10.2B
| $1.98M | ﹤0.01% |
14,328
-4,939
| -26% | -$647K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $2.66B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 23% of assets, down from 26% a quarter earlier, followed by Technology and Healthcare.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.